WHO Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

GAITHERSBURG, Md., Nov. 29, 2022. Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials